Intravitreal therapy for vein occlusive disease: promising in the short term

Article

Intravitreal therapy for venous occlusive disease is promising in the short term, however, multiple injections are needed, dosing schedules are presently unclear, and rebound has to be evaluated.

Intravitreal therapy for venous occlusive disease is promising in the short term, however, multiple injections are needed, dosing schedules are presently unclear, and rebound has to be evaluated, said Peter Kaiser, MD, of the Cole Eye Institute, Cleveland Clinic, Cleveland, OH.

"Venous occlusive disease is the second leading cause of decreased visual acuity in diabetic retinopathy, with 25% of patients having worse than 20/200 vision," Dr. Kaiser said. Laser treatment was not effective for these patients in two randomized studies and observation is the only therapy for central vein occlusion, he said. Laser has shown more improvement for branch vein occlusion but, in the long term, results in only a one-line increase in vision, he added.

Steroids are an obvious choice for vein occlusion since they decrease vascular permeability, stabilize the blood-retinal barrier, and address periphlebitis, according to Dr. Kaiser. In all studies, visual acuity improved. However, the drugs are associated with increased IOP and cataract, he said. The Standard Care versus Corticosteroids for Retinal Vein Occlusion Study is taking a close look at the drugs for retinal vein occlusion.

Anti-vascular endothelial growth factor (VEGF) drugs are also being evaluated. Two doses (1 and 0.3 mg) of pegaptanib sodium (Macugen, OSI/Eyetech/Pfizer) were evaluated in a phase II study. After every 6-week dosing (five injections), the visual acuity increased with both doses, but the end result was not much better than that achieved with laser, Dr. Kaiser reported.

One injection of bevacizumab (Avastin, Genentech) achieves "very nice" clinical features and optical coherence tomography findings, according to Dr. Kaiser. After 4 months, however, the edema returns, he said. Similar results were achieved with ranibizumab (Lucentis, Genentech). The BRAVO and Cruise studies are enrolling patients to evaluate the use of ranibizumab versus controls for branch and central retinal vein occlusion.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.